A Comprehensive Guide to ICD-10 Codes for Endometrial Cancer

In the intricate world of healthcare, a code is never just a code. It is a story, a diagnosis, a treatment pathway, and a data point that ripples through the entire healthcare ecosystem. Nowhere is this truer than in oncology, where the specificity of a diagnosis can mean the difference between a standard treatment protocol and a highly targeted, personalized therapy. For endometrial cancer, the most common gynecologic malignancy in the developed world, mastering the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) is not merely an administrative task—it is a fundamental clinical competency.

This article is designed to be the definitive guide for medical coders, cancer registrars, healthcare administrators, billers, and clinical professionals who seek to navigate the complex landscape of ICD-10 coding for endometrial cancer. We will move beyond simple code lookup and delve into the “why” behind the “what,” connecting pathological findings, clinical staging, and treatment decisions directly to the alphanumeric sequences that define them in the digital health record. From the foundational code of C54.1 to the nuanced details of histology and laterality, we will equip you with the knowledge to code with confidence, accuracy, and a deep understanding of the clinical context. In doing so, you will not only ensure compliant reimbursement but also contribute to the high-quality data that drives research, improves patient outcomes, and shapes the future of cancer care.

Chapter 1: Understanding the Disease – A Primer on Endometrial Cancer

Before a single code can be accurately assigned, a foundational understanding of the disease itself is paramount. Endometrial cancer originates in the inner lining of the uterus, the endometrium. This tissue is dynamic, responding to hormonal cycles throughout a woman’s reproductive life, thickening in preparation for pregnancy and shedding during menstruation.

Anatomy and Physiology of the Endometrium
The uterus is a hollow, pear-shaped organ. Its wall is composed of three layers:

1. Perimetrium: The outer serosal layer.

2. Myometrium: The thick, muscular middle layer.

3. Endometrium: The inner mucous membrane layer where endometrial cancer arises.

Pathogenesis: How Endometrial Cancer Develops
Approximately 80-90% of endometrial cancers are classified as Type I. These are estrogen-dependent, typically low-grade, and have a favorable prognosis. They often arise in a background of endometrial hyperplasia (an overgrowth of the endometrial lining) and are associated with risk factors like obesity, nulliparity, and late menopause.

The remaining 10-20% are Type II cancers. These are estrogen-independent, often high-grade, and more aggressive, with a tendency for early spread and a poorer prognosis. They typically occur in older, postmenopausal women and are not preceded by hyperplasia.

Histopathological Subtypes: The Critical Determinant of Code Selection
The microscopic appearance of the cancer cells—the histology—is the single most important factor in selecting the correct ICD-10 code. The pathologist’s report is the gold standard for code assignment.

• Endometrioid Adenocarcinoma (M-8140/3): The most common subtype, accounting for 75-80% of cases. It is typically Type I.

• Serous Carcinoma (M-8441/3): A high-grade, aggressive Type II cancer.

• Clear Cell Carcinoma (M-8310/3): Another high-grade, Type II variant.

• Carcinosarcoma (Malignant Mixed Müllerian Tumor – MMT) (M-8980/3): A biphasic tumor containing both carcinomatous (epithelial) and sarcomatous (mesenchymal) elements. It is highly aggressive.

• Other rare types: Mucinous, squamous cell, and undifferentiated carcinomas.

Staging and Grading: The FIGO and TNM Systems Explained
While ICD-10-CM codes for the neoplasm itself do not include stage, staging is critical for treatment and prognosis. The FIGO (International Federation of Gynecology and Obstetrics) system is most commonly used.

• Stage I: Tumor confined to the uterine corpus.

• Stage II: Tumor invades the cervical stroma.

• Stage III: Local and/or regional spread.

• Stage IV: Distant metastasis.

Grading (G) refers to how much the tumor cells resemble normal tissue (differentiation).

• G1: Well-differentiated (low-grade).

• G2: Moderately differentiated (intermediate-grade).

• G3: Poorly differentiated (high-grade).

Chapter 2: The ICD-10-CM Ecosystem – An Overview for the Oncology Coder

The ICD-10-CM manual is a structured, hierarchical system. Understanding its organization is key to efficient and accurate coding.

The Structure of the ICD-10-CM Manual

• Chapter 2: Neoplasms (C00-D49): This is where all codes for endometrial cancer are located.

• Block C00-C96: Malignant Neoplasms

• Category C51-C58: Malignant neoplasms of female genital organs.

• Category C54: Malignant neoplasm of corpus uteri. This is our primary category.

The Neoplasm Table: Your Primary Navigational Tool
The Alphabetic Index often directs you to the Neoplasm Table. In this table, you would look up “Endometrium” to find the correct code based on the anatomical site and the behavior (malignant primary, malignant secondary, in situ, etc.).

Conventions, Symbols, and Instructional Notes
Pay close attention to:

• “Code also”: Instructs you to sequence two codes, often for the tumor and its histology.

• “Use additional code”: Requires an additional code to provide more information, such as a symptom or risk factor.

• Excludes1 and Excludes2 notes: Critical for preventing coding errors by clarifying what is and is not included under a code.

Chapter 3: Deconstructing the Core Codes – C54.1 and Its Companions

The category C54 is the home for cancers of the uterine corpus (the body of the uterus).

The Foundation Code: C54.1 (Malignant Neoplasm of Endometrium)
This is the default and most frequently used code for a primary malignant tumor originating specifically in the endometrium. It is used when the pathology report confirms an endometrial origin.

Adjacent and Overlapping Sites: C54.0, C54.2, C54.8, and C54.9

• C54.0 (Isthmus): The isthmus is the lower, narrow part of the uterus, adjacent to the cervix. A tumor located here requires this specific code.

• C54.2 (Myometrium): If a tumor arises primarily in the myometrium (the muscle layer), which is rare, this code would be used. More commonly, the endometrium is the primary site with myometrial invasion, which is still coded to C54.1.

• C54.8 (Overlapping lesion of corpus uteri): Used when the tumor involves two or more contiguous sites within the corpus uteri (e.g., endometrium and myometrium) and the medical record does not specify a single point of origin.

• C54.9 (Corpus uteri, unspecified): A nonspecific code to be used only when the medical documentation is insufficient to assign a more specific code from category C54. This should be avoided whenever possible.

When the Origin is Unclear: C55 (Malignant Neoplasm of Uterus, Part Unspecified)
This code is used only when the physician’s documentation is vague and does not specify whether the cancer originated in the cervix (C53.-) or the corpus uteri (C54.-). It is a code of last resort and should be clarified with the provider.

Chapter 4: The Crucial 5th and 6th Characters – Specifying Histology

This is where ICD-10-CM demonstrates its power of specificity. For many neoplasms, you must use an additional code from Chapter 2 to identify the exact histology.

The “Code Also” and “Use Additional Code” Instructions
For codes in the C54.- category, the official guidelines include the instruction: “Code also any functional activity.” In the context of neoplasms, this is interpreted as requiring an additional code for the histology. This is a non-negotiable part of accurate coding for endometrial cancer.

Coding for Adenocarcinoma (M-8140/3) and Its Variants
The histology code for the most common type is M-8140/3 (Adenocarcinoma, NOS). If the pathology report specifies a variant, you must use the more specific code.

• Endometrioid Adenocarcinoma: M-8380/3

• Endometrioid Adenocarcinoma with Squamous Differentiation: M-8382/3

Coding for Carcinosarcoma (M-8980/3) – Malignant Mixed Müllerian Tumor (MMMT)
This highly aggressive tumor has its own specific histology code: M-8980/3. It is critical to code this correctly as it signifies a completely different disease biology, treatment approach, and prognosis compared to typical endometrioid adenocarcinoma.

Coding for Rare Histologies

• Serous Carcinoma: M-8441/3

• Clear Cell Carcinoma: M-8310/3

 Comprehensive Guide to Endometrial Cancer Histology Codes

Chapter 5: Sequencing and Application – Real-World Coding Scenarios

Let’s apply this knowledge to practical scenarios.

Scenario 1: Initial Diagnosis and Workup
A 62-year-old female presents to her gynecologist with postmenopausal bleeding. A transvaginal ultrasound shows a thickened endometrium. An endometrial biopsy is performed.

• Primary Diagnosis Code: R93.8 (Abnormal findings on diagnostic imaging of other body structures) – for the thickened endometrium.

• Symptom Code: N95.0 (Postmenopausal bleeding).

• Procedure Code: (CPT) for the endometrial biopsy.

• Note: The cancer code is not assigned until there is a confirmed pathological diagnosis.

Scenario 2: Post-Hysterectomy with Final Pathology
The patient from Scenario 1 undergoes a total hysterectomy with bilateral salpingo-oophorectomy. The final pathology report states: “Endometrioid adenocarcinoma, FIGO Grade 1, invading less than 50% of the myometrium.”

• Primary Diagnosis Code: C54.1 (Malignant neoplasm of endometrium)

• Histology Code: M-8380/3 (Endometrioid adenocarcinoma)

• Sequencing: C54.1 is the principal diagnosis. M-8380/3 is listed as a secondary diagnosis.

Scenario 3: Active Treatment with Chemotherapy and Radiation
A patient with a known history of uterine serous carcinoma (C54.1, M-8441/3) presents for her first cycle of adjuvant chemotherapy with carboplatin and paclitaxel.

• Primary Diagnosis Code: C54.1 (Malignant neoplasm of endometrium)

• Histology Code: M-8441/3 (Serous cystadenocarcinoma, NOS)

• Encounter Reason: Z51.11 (Encounter for antineoplastic chemotherapy)

Scenario 4: Encounter for Surveillance and Follow-Up
A patient, status post total hysterectomy two years ago for Stage I endometrial cancer, presents for her annual follow-up exam. She is currently disease-free.

• Primary Diagnosis Code: Z08 (Encounter for follow-up examination after completed treatment for malignant neoplasm). An additional code from Z85.4- can be used to specify the personal history.

• Specific Code: Z85.42 (Personal history of malignant neoplasm of corpus uteri)

Scenario 5: Coding for Complications and Comorbidities
A patient undergoing chemotherapy for endometrial cancer is admitted for management of severe neutropenia.

• Principal Diagnosis Code: D70.1 (Neutropenia resulting from cancer chemotherapy)

• Secondary Diagnosis Codes: C54.1, T45.1X5A (Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter), and the appropriate histology code.

Chapter 6: Beyond the Primary Diagnosis – Essential Secondary Codes

A complete record requires coding all relevant factors.

Coding for Symptoms: N95.0 (Postmenopausal bleeding), R10.2 (Pelvic and perineal pain).
Coding for Risk Factors: E66.9 (Obesity, unspecified), I10 (Essential hypertension).
Coding for Treatment Effects: L89.313 (Pressure ulcer of sacral region), G62.0 (Drug-induced polyneuropathy).
Z-Codes:

• Z51.11: Encounter for antineoplastic chemotherapy.

• Z51.0: Encounter for radiotherapy.

• Z08: Encounter for follow-up exam after cancer treatment.

• Z85.42: Personal history of malignant neoplasm of corpus uteri.

• Z80.49: Family history of malignant neoplasm of other genital organs.

Chapter 7: The Impact of Precision – Reimbursement, Analytics, and Patient Care

Accurate coding is the linchpin of the healthcare financial system. It determines the assignment of Diagnosis-Related Groups (DRGs) for inpatient stays and Ambulatory Payment Classifications (APCs) for outpatient services. A miscoded histology (e.g., coding a low-grade endometrioid as a high-grade serous) could lead to incorrect reimbursement and skew hospital performance metrics.

Furthermore, this coded data is the lifeblood of National Cancer Registries. It is used to track incidence, prevalence, survival rates, and treatment patterns. This data informs public health policy, guides resource allocation, and identifies populations at risk. For clinical research, precise coding allows for the accurate identification of patient cohorts for clinical trials, accelerating the development of new therapies.

Chapter 8: Common Pitfalls and How to Avoid Them

1. Confusing Endometrial (C54.1) and Cervical (C53.-) Cancer: Always verify the primary site in the pathology report.

2. Misinterpreting Histology Reports: Do not assume “adenocarcinoma” is always M-8140/3. Look for specific descriptors like “endometrioid” or “serous.”

3. Overlooking Status Updates: Once a patient has completed treatment and is in remission, the encounter reason shifts from the active cancer code (C54.1) to a follow-up (Z08) or history (Z85.42) code for surveillance visits.

4. Failing to Code to the Highest Level of Specificity: Using C54.9 when C54.1 is available, or omitting the histology code, is a coding failure that impacts data integrity and reimbursement.

Chapter 9: The Future of Coding – ICD-11 and the Evolution of Precision Medicine

The World Health Organization’s ICD-11 represents a significant shift towards a more modern, digital-friendly structure. The coding for endometrial cancer becomes more integrated.

• Example ICD-11 Code: 2C76.0 & XH1KT2 (Adenocarcinoma of endometrium). The structure allows for easier linking of topography and morphology.

Furthermore, the rise of molecular profiling is reclassifying endometrial cancer beyond histology. Categories now include:

• POLE-mutated: Ultra-mutated, excellent prognosis.

• Mismatch Repair Deficient (dMMR): Hypermutated, responsive to immunotherapy.

• p53-mutated: Copy-number high, poor prognosis (includes many serous cancers).
  While these are not yet directly reflected in ICD-10-CM codes, they are increasingly documented and may be captured with additional codes (e.g., R90.89 for other abnormal findings on diagnostic imaging, though not ideal). The coder of the future must be prepared to integrate this complex molecular data.

Conclusion: The Coder as a Vital Member of the Oncology Team

In the fight against endometrial cancer, precision is paramount—from the pathologist’s microscope to the surgeon’s skill and the oncologist’s treatment plan. The medical coder provides the critical link that translates this clinical precision into actionable data. By mastering the nuances of ICD-10-CM, from the foundational C54.1 to the detailed histology codes and essential Z-codes, you cease to be a mere abstractor and become a vital data architect. Your work ensures financial stability for the institution, fuels the research that leads to new cures, and, ultimately, contributes to the high-quality, data-driven care that every patient deserves.

Frequently Asked Questions (FAQs)

Q1: What is the correct ICD-10 code for a personal history of endometrial cancer?
A: The correct code is Z85.42 (Personal history of malignant neoplasm of corpus uteri). This is used when the cancer has been eradicated and the patient is presenting for routine follow-up or for an unrelated problem.

Q2: How do I code a patient who is status post-hysterectomy for endometrial cancer and is now receiving chemotherapy for a recurrence?
A: If the cancer has recurred (e.g., in the pelvis, lymph nodes, or as a distant metastasis), you would return to using the active cancer code C54.1 (or a code for the metastatic site if that is the focus of treatment) as the principal diagnosis, along with the appropriate histology code. The code for the encounter would be Z51.11 (Encounter for antineoplastic chemotherapy).

Q3: What is the difference between C54.8 and C54.9?
A: C54.8 (Overlapping lesion) is used when the tumor involves two or more contiguous sites within the corpus uteri (e.g., the medical record states the tumor is located in both the endometrium and the myometrium). C54.9 (Corpus uteri, unspecified) is a nonspecific code used only when the provider’s documentation is so vague that you cannot determine if it’s the endometrium, myometrium, etc. C54.9 should be a last resort.

Q4: Do I always need to use a histology code with C54.1?
A: Yes, per the ICD-10-CM official guidelines, you must “code also” the histology. The histology code provides essential clinical detail and is required for complete and accurate coding.

Q5: How do I code a patient with endometrial intraepithelial neoplasia (EIN)?
A: EIN is a pre-malignant condition. It is not cancer. The correct ICD-10 code is N85.03 (Endometrial intraepithelial neoplasia [EIN]).

Additional Resources

1. CDC – ICD-10-CM Official Guidelines for Coding and Reporting: https://www.cdc.gov/nchs/icd/icd-10-cm.htm (The definitive source for rules and updates).

2. American Cancer Society – Endometrial Cancer Details: https://www.cancer.org/cancer/types/endometrial-cancer.html (Excellent for clinical context).

3. National Cancer Institute – SEER Program: https://seer.cancer.gov/ (For statistics and registry information).

4. World Health Organization (WHO) Classification of Female Genital Tumours (5th Edition): The international standard for pathological classification.

5. American College of Obstetricians and Gynecologists (ACOG): https://www.acog.org/ (For clinical practice guidelines).

 

Date: September 29, 2025
Author: The Coding & Oncology Team
Disclaimer: The information contained in this article is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment. The author is not a licensed medical professional. Coding guidelines are subject to change; always refer to the most current official ICD-10-CM coding manuals and payer-specific policies.